ID   Hs 578T
AC   CVCL_0332
SY   HS 578T; Hs-578T; HS-578T; Hs_578t; Hs-578-T; HS-578-T; Hs 578.T; HS578T; Hs578T; Hs578t; HS0578T; 578T; HS578; Hs578; Homo sapiens No. 578, tumor cells
DR   BTO; BTO_0003885
DR   CLO; CLO_0004009
DR   EFO; EFO_0001192
DR   MCCL; MCC:0000228
DR   CLDB; cl1716
DR   CLDB; cl1717
DR   CLDB; cl5023
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-TABM-157
DR   ArrayExpress; E-TABM-244
DR   ATCC; CRL-7849
DR   ATCC; HTB-126
DR   BCRC; 60120
DR   BioGRID_ORCS_Cell_line; 654
DR   BioSample; SAMN03473213
DR   BioSample; SAMN10987893
DR   cancercelllines; CVCL_0332
DR   CCRID; 1101HUM-PUMC000670
DR   CCRID; 3101HUMTCHu127
DR   CCRID; 4201HUM-CCTCC00252
DR   CCTCC; GDC0252
DR   Cell_Model_Passport; SIDM00135
DR   ChEMBL-Cells; CHEMBL3307672
DR   ChEMBL-Targets; CHEMBL614645
DR   CLS; 305089
DR   Cosmic; 871142
DR   Cosmic; 875877
DR   Cosmic; 897418
DR   Cosmic; 904372
DR   Cosmic; 905957
DR   Cosmic; 921973
DR   Cosmic; 934524
DR   Cosmic; 974234
DR   Cosmic; 979715
DR   Cosmic; 997928
DR   Cosmic; 1010929
DR   Cosmic; 1017164
DR   Cosmic; 1018473
DR   Cosmic; 1027051
DR   Cosmic; 1044232
DR   Cosmic; 1046945
DR   Cosmic; 1047714
DR   Cosmic; 1092606
DR   Cosmic; 1136373
DR   Cosmic; 1175831
DR   Cosmic; 1176633
DR   Cosmic; 1218873
DR   Cosmic; 1235086
DR   Cosmic; 1287921
DR   Cosmic; 1289390
DR   Cosmic; 1305385
DR   Cosmic; 1312371
DR   Cosmic; 1430343
DR   Cosmic; 1473054
DR   Cosmic; 1518105
DR   Cosmic; 1603214
DR   Cosmic; 1609463
DR   Cosmic; 1998448
DR   Cosmic; 2009515
DR   Cosmic; 2164996
DR   Cosmic; 2301525
DR   Cosmic; 2560243
DR   Cosmic; 2668302
DR   Cosmic-CLP; 905957
DR   DepMap; ACH-000148
DR   DSMZ; ACC-781
DR   DSMZCellDive; ACC-781
DR   ECACC; 86082104
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 905957
DR   GEO; GSM2113
DR   GEO; GSM50182
DR   GEO; GSM50246
DR   GEO; GSM217581
DR   GEO; GSM219968
DR   GEO; GSM344346
DR   GEO; GSM344396
DR   GEO; GSM421868
DR   GEO; GSM750776
DR   GEO; GSM783962
DR   GEO; GSM799319
DR   GEO; GSM799382
DR   GEO; GSM839032
DR   GEO; GSM844563
DR   GEO; GSM844564
DR   GEO; GSM844565
DR   GEO; GSM846359
DR   GEO; GSM847392
DR   GEO; GSM847488
DR   GEO; GSM887098
DR   GEO; GSM888169
DR   GEO; GSM1008903
DR   GEO; GSM1053700
DR   GEO; GSM1153388
DR   GEO; GSM1172877
DR   GEO; GSM1181262
DR   GEO; GSM1181319
DR   GEO; GSM1214564
DR   GEO; GSM1238131
DR   GEO; GSM1374549
DR   GEO; GSM1374550
DR   GEO; GSM1669895
DR   GEO; GSM1833625
DR   GEO; GSM2124656
DR   IARC_TP53; 579
DR   IBRC; C10150
DR   ICLC; HTL00007
DR   KCB; KCB 2012025YJ
DR   KCLB; 30126
DR   LiGeA; CCLE_743
DR   LINCS_HMS; 50238
DR   LINCS_LDP; LCL-1315
DR   Lonza; 1444
DR   NCI-DTP; HS 578T
DR   PharmacoDB; Hs578T_614_2019
DR   PRIDE; PXD005292
DR   PRIDE; PXD005942
DR   PRIDE; PXD005946
DR   PRIDE; PXD008222
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0332
DR   PubChem_Cell_line; CVCL_0332
DR   SKY/M-FISH/CGH; 2663
DR   SLKBase; 3558
DR   Wikidata; Q54895774
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RX   DOI=10.25904/1912/1434;
RX   DOI=10.4172/2157-7145.S2-005;
RX   PubMed=283258;
RX   PubMed=761205;
RX   PubMed=864756;
RX   PubMed=1961733;
RX   PubMed=3335022;
RX   PubMed=7902062;
RX   PubMed=9331090;
RX   PubMed=10700174;
RX   PubMed=10969801;
RX   PubMed=15153330;
RX   PubMed=15677628;
RX   PubMed=15748285;
RX   PubMed=16142302;
RX   PubMed=16397213;
RX   PubMed=16541312;
RX   PubMed=16959974;
RX   PubMed=17088437;
RX   PubMed=17157791;
RX   PubMed=17932254;
RX   PubMed=18277095;
RX   PubMed=18386134;
RX   PubMed=18516279;
RX   PubMed=19372543;
RX   PubMed=19582160;
RX   PubMed=19593635;
RX   PubMed=20070913;
RX   PubMed=20164919;
RX   PubMed=21778573;
RX   PubMed=22068913;
RX   PubMed=22347499;
RX   PubMed=22384151;
RX   PubMed=22460905;
RX   PubMed=22585861;
RX   PubMed=22628656;
RX   PubMed=23151021;
RX   PubMed=23601657;
RX   PubMed=23856246;
RX   PubMed=23933261;
RX   PubMed=24009699;
RX   PubMed=24094812;
RX   PubMed=24162158;
RX   PubMed=24176112;
RX   PubMed=24279929;
RX   PubMed=24670534;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25892236;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=27377824;
RX   PubMed=27397505;
RX   PubMed=27807467;
RX   PubMed=28196595;
RX   PubMed=28287265;
RX   PubMed=28889351;
RX   PubMed=29671673;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
RX   PubMed=38861359;
WW   Info; ATCC; -; https://www.atcc.org/en/support/technical-support/faqs/morphology-and-growth-of-atcc-htb-126
WW   Info; MCLP; -; https://tcpaportal.org/mclp/
WW   Info; NCI DTP; NCI-60; https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW   Info; StRAP; -; https://strap.nci.nih.gov/celline_detail.php?sample_id=3
WW   Info; Synapse; JWGray panel; https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
WW   Info; Thermo Fisher; -; https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/h/cell-lines-detail-305.html
WW   Provider; Altogen; Xenograft model; https://altogenlabs.com/xenograft-models/breast-cancer-xenograft/hs578t-xenograft-model/
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: JWGray breast cancer cell line panel.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Part of: NCI-60 cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 34 hours (PubMed=18386134); ~48 hours (DSMZ=ACC-781); 53.8 hours (NCI-DTP=HS 578T); 32.35 hours (JWGray panel).
CC   HLA typing: A*03,24; B*35,40; C*03:04:01,04; DPB1*04:01,78:01; DQB1*05:01:01,06:02; DRB1*01,15:01:01 (PubMed=15748285).
CC   HLA typing: A*03:01,24:02; B*35:03,40:01; C*03:04,04:01; DQA1*03:02,03:02 (PubMed=25960936).
CC   HLA typing: A*03:01,24:02; B*35:03,40:01; C*03:04,04:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=19593635).
CC   Sequence variation: Mutation; HGNC; HGNC:5173; HRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012612; Zygosity=Heterozygous (PubMed=17088437; PubMed=19593635; PubMed=28889351).
CC   Sequence variation: Mutation; HGNC; HGNC:7427; MT-CYB; Simple; p.Ala125Thr (m.15119G>A); ClinVar=VCV000693829; Zygosity=Homoplasmic (PubMed=29671673).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Homozygous (PubMed=1961733; PubMed=16541312; PubMed=17088437; PubMed=18277095; PubMed=28889351).
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Genomics; Mitochondrial genome sequencing.
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Glycomics; N-glycan profiling.
CC   Omics: Metabolomics.
CC   Omics: Phenotyping; CRISPR screening.
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Phenotyping; Fluorescent probe library screening.
CC   Omics: Proteomics.
CC   Omics: Proteomics; Expression; Reverse-phase protein array.
CC   Omics: Proteomics; PTM; Glycoproteome.
CC   Omics: Proteomics; Quantitative.
CC   Omics: Transcriptomics; lncRNA profiling; RT-qPCR platform.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; miRNA profiling; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; Array-based CGH.
CC   Omics: Variations; CNV analysis.
CC   Omics: Variations; SNP array analysis.
CC   Genome ancestry: African=0.53%; Native American=0%; East Asian, North=1.71%; East Asian, South=0%; South Asian=0%; European, North=63.73%; European, South=34.01% (PubMed=30894373).
CC   Misspelling: HS758T; Cosmic=904372.
CC   Misspelling: Hs-587-T; Cosmic=1010929; Cosmic=1176633.
CC   Misspelling: HTB126; Note=Based on the ATCC catalog number.
CC   Discontinued: ATCC; CRL-7849; true.
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
ST   Source(s): ATCC=HTB-126; CCRID; Cosmic-CLP=905957; DSMZ=ACC-781; ECACC=86082104; KCLB=30126; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200; PubMed=28889351; Technion Genomics Center
ST   Amelogenin: X
ST   CSF1PO: 13
ST   D10S1248: 16
ST   D12S391: 19
ST   D13S317: 11
ST   D16S539: 9,12 (ATCC=HTB-126; CCRID; Cosmic-CLP=905957; ECACC=86082104; KCLB=30126; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200; PubMed=28889351; Technion Genomics Center)
ST   D16S539: 12 (DSMZ=ACC-781)
ST   D18S51: 16
ST   D19S433: 14,15
ST   D1S1656: 11,16
ST   D21S11: 29,32.2 (ATCC=HTB-126; CCRID; DSMZ=ACC-781; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200; Technion Genomics Center)
ST   D21S11: 32.2 (PubMed=28889351)
ST   D22S1045: 15,16
ST   D2S1338: 17,26
ST   D2S441: 14
ST   D3S1358: 16,17
ST   D5S818: 11
ST   D6S1043: 12
ST   D7S820: 10
ST   D8S1179: 13
ST   FGA: 23,24
ST   Penta D: 8,13
ST   Penta E: 13,14
ST   TH01: 9,9.3
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_S253 ! Hs 578.Mg
OI   CVCL_0807 ! Hs 578Bst
SX   Female
AG   74Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 51
//
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RA   Leibovitz A.;
RT   "Cell lines from human breast.";
RL   (In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York; USA (1994).
//
RX   DOI=10.25904/1912/1434;
RA   Morrison B.J.;
RT   "Breast cancer stem cells: tumourspheres and implications for therapy.";
RL   Thesis PhD (2010); Griffith University; Brisbane; Australia.
//
RX   DOI=10.4172/2157-7145.S2-005;
RA   Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M.R.,
RA   Hart R.P., Furtado M.R.;
RT   "STR profiling of human cell lines: challenges and possible solutions
RT   to the growing problem.";
RL   J. Forensic Res. 2 Suppl. 2:5-5(2011).
//
RX   PubMed=283258; DOI=10.1093/jnci/62.2.225;
RA   Smith H.S.;
RT   "In vitro properties of epithelial cell lines established from human
RT   carcinomas and nonmalignant tissue.";
RL   J. Natl. Cancer Inst. 62:225-230(1979).
//
RX   PubMed=761205;
RA   Smith H.S., Springer E.L., Hackett A.J.;
RT   "Nuclear ultrastructure of epithelial cell lines derived from human
RT   carcinomas and nonmalignant tissues.";
RL   Cancer Res. 39:332-344(1979).
//
RX   PubMed=864756; DOI=10.1093/jnci/58.6.1795;
RA   Hackett A.J., Smith H.S., Springer E.L., Owens R.B., Nelson-Rees W.A.,
RA   Riggs J.L., Gardner M.B.;
RT   "Two syngeneic cell lines from human breast tissue: the aneuploid
RT   mammary epithelial (Hs578T) and the diploid myoepithelial (Hs578Bst)
RT   cell lines.";
RL   J. Natl. Cancer Inst. 58:1795-1806(1977).
//
RX   PubMed=1961733; DOI=10.1073/pnas.88.23.10657; PMCID=PMC52989;
RA   Runnebaum I.B., Nagarajan M., Bowman M., Soto D., Sukumar S.;
RT   "Mutations in p53 as potential molecular markers for human breast
RT   cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:10657-10661(1991).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=7902062;
RA   de la Torre M., Hao X.-Y., Larsson R., Nygren P., Tsuruo T.,
RA   Mannervik B., Bergh J.;
RT   "Characterization of four doxorubicin adapted human breast cancer cell
RT   lines with respect to chemotherapeutic drug sensitivity, drug
RT   resistance associated membrane proteins and glutathione
RT   transferases.";
RL   Anticancer Res. 13:1425-1430(1993).
//
RX   PubMed=9331090;
RA   O'Connor P.M., Jackman J., Bae I., Myers T.G., Fan S.-J., Mutoh M.,
RA   Scudiero D.A., Monks A., Sausville E.A., Weinstein J.N., Friend S.H.,
RA   Fornace A.J. Jr., Kohn K.W.;
RT   "Characterization of the p53 tumor suppressor pathway in cell lines of
RT   the National Cancer Institute anticancer drug screen and correlations
RT   with the growth-inhibitory potency of 123 anticancer agents.";
RL   Cancer Res. 57:4285-4300(1997).
//
RX   PubMed=10700174; DOI=10.1038/73432;
RA   Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T.,
RA   Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A.,
RA   Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N.,
RA   Botstein D., Brown P.O.;
RT   "Systematic variation in gene expression patterns in human cancer cell
RT   lines.";
RL   Nat. Genet. 24:227-235(2000).
//
RX   PubMed=10969801;
RA   Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y.,
RA   Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.;
RT   "Comparative genomic hybridization analysis of 38 breast cancer cell
RT   lines: a basis for interpreting complementary DNA microarray data.";
RL   Cancer Res. 60:4519-4525(2000).
//
RX   PubMed=15153330; DOI=10.1593/neo.3292; PMCID=PMC1502105;
RA   Watts G.S., Oshiro M.M., Junk D.J., Wozniak R.J., Watterson S.J.,
RA   Domann F.E., Futscher B.W.;
RT   "The acetyltransferase p300/CBP-associated factor is a p53 target gene
RT   in breast tumor cells.";
RL   Neoplasia 6:187-194(2004).
//
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
//
RX   PubMed=15748285; DOI=10.1186/1479-5876-3-11; PMCID=PMC555742;
RA   Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L.,
RA   Morse H.C. 3rd, Stroncek D., Marincola F.M.;
RT   "HLA class I and II genotype of the NCI-60 cell lines.";
RL   J. Transl. Med. 3:11.1-11.8(2005).
//
RX   PubMed=16142302; DOI=10.3892/ijo.27.4.881;
RA   de Longueville F., Lacroix M., Barbuto A.-M., Bertholet V., Gallo D.,
RA   Larsimont D., Marcq L., Zammatteo N., Boffe S., Leclercq G.,
RA   Remacle J.;
RT   "Molecular characterization of breast cancer cell lines by a
RT   low-density microarray.";
RL   Int. J. Oncol. 27:881-892(2005).
//
RX   PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853;
RA   Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M.,
RA   van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.;
RT   "BRCA1 mutation analysis of 41 human breast cancer cell lines reveals
RT   three new deleterious mutants.";
RL   Cancer Res. 66:41-45(2006).
//
RX   PubMed=16541312; DOI=10.1007/s10549-006-9186-z;
RA   Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.;
RT   "Thirteen new p53 gene mutants identified among 41 human breast cancer
RT   cell lines.";
RL   Breast Cancer Res. Treat. 99:97-101(2006).
//
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.E.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.-S.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
//
RX   PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832;
RA   Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C.,
RA   O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L.,
RA   Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S.,
RA   Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C.,
RA   Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A.,
RA   Mironenko T., Parker A., Perry J., Raine K.M., Richardson D.,
RA   Shepherd R., Small A., Smith R., Solomon H., Stephens P.J.,
RA   Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.;
RT   "Mutation analysis of 24 known cancer genes in the NCI-60 cell line
RT   set.";
RL   Mol. Cancer Ther. 5:2606-2612(2006).
//
RX   PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008; PMCID=PMC2730521;
RA   Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T.,
RA   Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T.,
RA   DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D.,
RA   Albertson D.G., Waldman F.M., McCormick F., Dickson R.B.,
RA   Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.;
RT   "A collection of breast cancer cell lines for the study of
RT   functionally distinct cancer subtypes.";
RL   Cancer Cell 10:515-527(2006).
//
RX   PubMed=17932254; DOI=10.1126/science.1145720;
RA   Wood L.D., Parsons D.W., Jones S., Lin J., Sjoblom T., Leary R.J.,
RA   Shen D., Boca S.M., Barber T.D., Ptak J., Silliman N., Szabo S.,
RA   Dezso Z., Ustyanksky V., Nikolskaya T., Nikolsky Y., Karchin R.,
RA   Wilson P.A., Kaminker J.S., Zhang Z.-M., Croshaw R., Willis J.E.,
RA   Dawson D., Shipitsin M., Willson J.K.V., Sukumar S., Polyak K.,
RA   Park B.H., Pethiyagoda C.L., Pant P.V.K., Ballinger D.G., Sparks A.B.,
RA   Hartigan J., Smith D.R., Suh E., Papadopoulos N., Buckhaults P.,
RA   Markowitz S.D., Parmigiani G., Kinzler K.W., Velculescu V.E.,
RA   Vogelstein B.;
RT   "The genomic landscapes of human breast and colorectal cancers.";
RL   Science 318:1108-1113(2007).
//
RX   PubMed=18277095; DOI=10.4161/cbt.7.5.5712;
RA   Berglind H., Pawitan Y., Kato S., Ishioka C., Soussi T.;
RT   "Analysis of p53 mutation status in human cancer cell lines: a
RT   paradigm for cell line cross-contamination.";
RL   Cancer Biol. Ther. 7:699-708(2008).
//
RX   PubMed=18386134; DOI=10.1007/s10585-008-9169-z;
RA   Hughes L., Malone C., Chumsri S., Burger A.M., McDonnell S.;
RT   "Characterisation of breast cancer cell lines and establishment of a
RT   novel isogenic subclone to study migration, invasion and
RT   tumourigenicity.";
RL   Clin. Exp. Metastasis 25:549-557(2008).
//
RX   PubMed=18516279; DOI=10.1016/j.molonc.2007.02.004; PMCID=PMC2391005;
RA   Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R.,
RA   Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H.,
RA   Petersen O.W., Gray J.W., Bissell M.J.;
RT   "The morphologies of breast cancer cell lines in three-dimensional
RT   assays correlate with their profiles of gene expression.";
RL   Mol. Oncol. 1:84-96(2007).
//
RX   PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921; PMCID=PMC4020356;
RA   Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y.,
RA   Chanock S.J., Weinstein J.N.;
RT   "DNA fingerprinting of the NCI-60 cell line panel.";
RL   Mol. Cancer Ther. 8:713-724(2009).
//
RX   PubMed=19582160; DOI=10.1371/journal.pone.0006146; PMCID=PMC2702084;
RA   Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J.,
RA   Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D.,
RA   Pollack J.R.;
RT   "Molecular profiling of breast cancer cell lines defines relevant
RT   tumor models and provides a resource for cancer gene discovery.";
RL   PLoS ONE 4:e6146.1-e6146.16(2009).
//
RX   PubMed=19593635; DOI=10.1007/s10549-009-0460-8;
RA   Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F.,
RA   Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J.,
RA   Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M.,
RA   Zwarthoff E.C., Teunisse A.F.A.S., van der Spek P.J., Klijn J.G.M.,
RA   Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G.,
RA   den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.;
RT   "Distinct gene mutation profiles among luminal-type and basal-type
RT   breast cancer cell lines.";
RL   Breast Cancer Res. Treat. 121:53-64(2010).
//
RX   PubMed=20070913; DOI=10.1186/1471-2407-10-15; PMCID=PMC2836299;
RA   Tsuji K., Kawauchi S., Saito S., Furuya T., Ikemoto K., Nakao M.,
RA   Yamamoto S., Oka M., Hirano T., Sasaki K.;
RT   "Breast cancer cell lines carry cell line-specific genomic alterations
RT   that are distinct from aberrations in breast cancer tissues:
RT   comparison of the CGH profiles between cancer cell lines and primary
RT   cancer tissues.";
RL   BMC Cancer 10:15.1-15.10(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113;
RA   Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21778573; DOI=10.3233/BD-2010-0307; PMCID=PMC3532890;
RA   Chavez K.J., Garimella S.V., Lipkowitz S.;
RT   "Triple negative breast cancer cell lines: one tool in the search for
RT   better treatment of triple negative breast cancer.";
RL   Breast Dis. 32:35-48(2010).
//
RX   PubMed=22068913; DOI=10.1073/pnas.1111840108; PMCID=PMC3219108;
RA   Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J.,
RA   Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V.,
RA   Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R.,
RA   Ambudkar S.V., Gottesman M.M.;
RT   "Redefining the relevance of established cancer cell lines to the
RT   study of mechanisms of clinical anti-cancer drug resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
//
RX   PubMed=22347499; DOI=10.1371/journal.pone.0031628; PMCID=PMC3276511;
RA   Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.;
RT   "Mass homozygotes accumulation in the NCI-60 cancer cell lines as
RT   compared to HapMap trios, and relation to fragile site location.";
RL   PLoS ONE 7:e31628.1-e31628.9(2012).
//
RX   PubMed=22384151; DOI=10.1371/journal.pone.0032096; PMCID=PMC3285665;
RA   Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H.,
RA   Yoon C.N., Chang Y.-T.;
RT   "Identification of cancer cell-line origins using fluorescence
RT   image-based phenomic screening.";
RL   PLoS ONE 7:e32096.1-e32096.8(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224; PMCID=PMC5057396;
RA   Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K.,
RA   Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y.,
RA   van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J.,
RA   Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P.,
RA   Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L.,
RA   Rottapel R., Neel B.G., Moffat J.;
RT   "Essential gene profiles in breast, pancreatic, and ovarian cancer
RT   cells.";
RL   Cancer Discov. 2:172-189(2012).
//
RX   PubMed=22628656; DOI=10.1126/science.1218595; PMCID=PMC3526189;
RA   Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L.,
RA   Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.;
RT   "Metabolite profiling identifies a key role for glycine in rapid
RT   cancer cell proliferation.";
RL   Science 336:1040-1044(2012).
//
RX   PubMed=23151021; DOI=10.1186/1471-2164-13-619; PMCID=PMC3546428;
RA   Grigoriadis A., Mackay A., Noel E., Wu P.-J., Natrajan R., Frankum J.,
RA   Reis-Filho J.S., Tutt A.;
RT   "Molecular characterisation of cell line models for triple-negative
RT   breast cancers.";
RL   BMC Genomics 13:619.1-619.14(2012).
//
RX   PubMed=23601657; DOI=10.1186/bcr3415; PMCID=PMC3672661;
RA   Riaz M., van Jaarsveld M.T.M., Hollestelle A.,
RA   Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J.,
RA   Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A.,
RA   Martens J.W.M.;
RT   "miRNA expression profiling of 51 human breast cancer cell lines
RT   reveals subtype and driver mutation-specific miRNAs.";
RL   Breast Cancer Res. 15:R33.1-R33.17(2013).
//
RX   PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342; PMCID=PMC4893961;
RA   Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L.,
RA   Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L.,
RA   Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.;
RT   "The exomes of the NCI-60 panel: a genomic resource for cancer biology
RT   and systems pharmacology.";
RL   Cancer Res. 73:4372-4382(2013).
//
RX   PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018;
RA   Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C.,
RA   Wilhelm M., Kuster B.;
RT   "Global proteome analysis of the NCI-60 cell line panel.";
RL   Cell Rep. 4:609-620(2013).
//
RX   PubMed=24009699; DOI=10.1371/journal.pone.0072704; PMCID=PMC3751845;
RA   Liu X., Nie H., Zhang Y.-B., Yao Y.-F., Maitikabili A., Qu Y.-P.,
RA   Shi S.-L., Chen C.-Y., Li Y.;
RT   "Cell surface-specific N-glycan profiling in breast cancer.";
RL   PLoS ONE 8:e72704.1-e72704.11(2013).
//
RX   PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020; PMCID=PMC3931310;
RA   Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A.,
RA   Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K.,
RA   McCormick F., Gray J.W.;
RT   "Glutamine sensitivity analysis identifies the xCT antiporter as a
RT   common triple-negative breast tumor therapeutic target.";
RL   Cancer Cell 24:450-465(2013).
//
RX   PubMed=24162158; DOI=10.1007/s10549-013-2743-3; PMCID=PMC3832776;
RA   Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M.,
RA   Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.;
RT   "Characterization of cell lines derived from breast cancers and normal
RT   mammary tissues for the study of the intrinsic molecular subtypes.";
RL   Breast Cancer Res. Treat. 142:237-255(2013).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110; PMCID=PMC3937590;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=24279929; DOI=10.1186/2049-3002-1-20; PMCID=PMC4178206;
RA   Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R.,
RA   Hirshfield K.M., Oltvai Z.N., Vazquez A.;
RT   "The metabolic demands of cancer cells are coupled to their size and
RT   protein synthesis rates.";
RL   Cancer Metab. 1:20.1-20.13(2013).
//
RX   PubMed=24670534; DOI=10.1371/journal.pone.0092047; PMCID=PMC3966786;
RA   Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.;
RT   "High resolution copy number variation data in the NCI-60 cancer cell
RT   lines from whole genome microarrays accessible through CellMiner.";
RL   PLoS ONE 9:e92047.1-e92047.15(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25892236; DOI=10.1016/j.celrep.2015.03.050; PMCID=PMC4425736;
RA   Lawrence R.T., Perez E.M., Hernandez D., Miller C.P., Haas K.M.,
RA   Irie H.Y., Lee S.-I., Blau C.A., Villen J.;
RT   "The proteomic landscape of triple-negative breast cancer.";
RL   Cell Rep. 11:630-644(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27377824; DOI=10.1038/sdata.2016.52; PMCID=PMC4932877;
RA   Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J.,
RA   Vandesompele J.;
RT   "Long non-coding RNA expression profiling in the NCI60 cancer cell
RT   line panel using high-throughput RT-qPCR.";
RL   Sci. Data 3:160052.1-160052.6(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27807467; DOI=10.1186/s13100-016-0078-4; PMCID=PMC5087121;
RA   Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J.,
RA   Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.;
RT   "A map of mobile DNA insertions in the NCI-60 human cancer cell
RT   panel.";
RL   Mob. DNA 7:20.1-20.11(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470; PMCID=PMC5557415;
RA   Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.;
RT   "Glycoproteins in claudin-low breast cancer cell lines have a unique
RT   expression profile.";
RL   J. Proteome Res. 16:1391-1400(2017).
//
RX   PubMed=28889351; DOI=10.1007/s10549-017-4496-x;
RA   Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L.,
RA   Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E.,
RA   Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J.,
RA   Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E.,
RA   Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F.,
RA   Lakhani S.R.;
RT   "Multidimensional phenotyping of breast cancer cell lines to guide
RT   preclinical research.";
RL   Breast Cancer Res. Treat. 167:289-301(2018).
//
RX   PubMed=29671673; DOI=10.1080/24701394.2018.1461852;
RA   Hedberg A., Knutsen E., Lovhaugen A.S., Jorgensen T.E., Perander M.,
RA   Johansen S.D.;
RT   "Cancer-specific SNPs originate from low-level heteroplasmic variants
RT   in human mitochondrial genomes of a matched cell line pair.";
RL   Mitochondrial DNA A. DNA Mapp. Seq. Anal. 30:82-91(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//
RX   PubMed=38861359; DOI=10.1158/0008-5472.CAN-23-3031; PMCID=PMC11292194;
RA   Kunkel M.W., Coussens N.P., Morris J., Taylor R.C., Dexheimer T.S.,
RA   Jones E.M., Doroshow J.H., Teicher B.A.;
RT   "HTS384 NCI60: the next phase of the NCI60 screen.";
RL   Cancer Res. 84:2403-2416(2024).
//